Integrilin Disease Interactions
There are 2 disease interactions with Integrilin (eptifibatide).
Eptifibatide (applies to Integrilin) renal dysfunction
Major Potential Hazard, High plausibility.
The use of eptifibatide is contraindicated in patients dependent of dialysis. Approximately 50% of eptifibatide is cleared by the kidney in patients with normal renal function. Total drug clearance is decreased by approximately 50% and steady-state plasma eptifibatide concentrations are doubled in patients with an estimated CrCl <50 mL/min. Therefore, the infusion dose should be reduced to 1 mcg/kg/min in such patients Clinical monitoring of renal function is recommended.
GpIIb/IIIa platelet inhibitors (applies to Integrilin) bleeding risks
Major Potential Hazard, High plausibility. Applicable conditions: Brain/Intracranial Tumor, Thrombocytopathy, Cerebral Vascular Disorder, Hypertension, Coagulation Defect, Thrombocytopenia
The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.
Switch to professional interaction data
Integrilin drug interactions
There are 151 drug interactions with Integrilin (eptifibatide).
Integrilin alcohol/food interactions
There is 1 alcohol/food interaction with Integrilin (eptifibatide).
More about Integrilin (eptifibatide)
- Integrilin consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: glycoprotein platelet inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Plavix
Plavix (clopidogrel) is used to prevent blood clots after a recent heart attack or stroke. Includes ...
Lovenox
Lovenox is used to prevent deep vein thrombosis (DVT) which can lead to blood clots in the lungs ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Brilinta
Brilinta (ticagrelor) is used to lower your risk of having a stroke or serious heart problems after ...
Effient
Effient is used to prevent blood clots forming in acute coronary syndrome patients. Learn about ...
Ticagrelor
Ticagrelor is used for acute coronary syndrome, cardiovascular risk reduction, coronary artery ...
Prasugrel
Prasugrel is used for acute coronary syndrome, heart attack, myocardial infarction, prophylaxis
Enoxaparin
Enoxaparin is used for acute coronary syndrome, angina, deep vein thrombosis, deep vein thrombosis ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.